Understanding the mechanisms behind antibiotic resistance reveals the pressing need for innovative solutions in the pharmaceutical landscape. Presenting TAXIS Pharmaceuticals' Commitment to Innovation: TXA709. TAXIS is dedicated to developing novel therapies that specifically target resistant strains of bacteria.
Our new white paper delves into the global scope of AMR, shedding light on its widespread impact and the variability of its effects across different regions. The paper outlines actionable strategies to combat AMR, such as enhancing global surveillance systems, advocating for responsible antibiotic use, investing in the development of innovative treatments, and fostering international collaboration.
The prospective bill, the Pasteur Act, is one potential strategy to help in these areas, and incentivize pharmaceutical companies to develop these essential therapies. This article was originally published on contagionlive.com.
© 2024 TAXIS Pharmaceuticals, Inc.
